Ease Regulations For Affordable Biosimilars, Groups Urge
This article was originally published in PharmAsia News
Executive Summary
Present biosimilar guidelines pose regulatory barriers to the launch of affordable medicines and are guided by transnational companies, claim leading civil society groups. They are calling for a review of international regulations that can facilitate the launch of lower-priced biotherapeutics.